Page last updated: 2024-08-17

bromodeoxyuridine and Cerebral Cortical Dysplasia

bromodeoxyuridine has been researched along with Cerebral Cortical Dysplasia in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, C; Bonthron, DT; Boycot, KM; Braun, KPJ; Dobyns, WB; Faivre, L; Fry, AE; Giamanco, KA; Gripp, KW; Hevner, RF; Hodge, RD; Johnson, CA; Kholmanskikh, SS; Logan, CV; Majewski, J; Mancini, GM; Mirzaa, G; Pang, K; Parry, DA; Pilz, DT; Rivière, JB; Roberts, N; Ross, ME; Schwartzentruber, J; Sheridan, EG; Singh, S; St-Onge, J; Steinraths, M; Sweeney, E; van Esch, H; Vanstone, M; Verbeek, N; Wieczorek, D1

Other Studies

1 other study(ies) available for bromodeoxyuridine and Cerebral Cortical Dysplasia

ArticleYear
De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.
    Nature genetics, 2014, Volume: 46, Issue:5

    Topics: Abnormalities, Multiple; Animals; Base Sequence; Blotting, Western; Bromodeoxyuridine; Cyclin D2; Electroporation; Exome; Female; HEK293 Cells; Humans; Hydrocephalus; Immunohistochemistry; Malformations of Cortical Development; Megalencephaly; Mice; Microscopy, Fluorescence; Molecular Sequence Data; Mutagenesis, Site-Directed; Polydactyly; Sequence Analysis, DNA; Syndrome

2014